Il Libro Italiano della Talidomide... - a.na.d.ma.

More documents

Recommendations

Info

42 MARIO BOCCADOROBibliografia1Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999;341:1565-71.2Barlogie B, Desikan R, Eddlemon P, et al. Extended survival in advanced and refractory multiple myeloma after single-agentthalidomide: identification of prognostic factors in a phase 2 study of 169 patients. Blood 2001; 98:492-94.3Grosbois B, Bellissant E, Moreau P et al. Thalidomide (Thal) in the treatment of advanced multiple myeloma (MM): aprospective study of 120 patients. Blood 2001; 98:689a.4Neben K, Moehler T, Kraemer A, et al. Response to thalidomide in progressive multiple myeloma is not mediated byinhibition of angiogenic cytokine secretion. Br J Haematol 2001; 115:605-08.5Neben K, Moehler T, Benner A, et al. Dose-dependent effect of thalidomide on overall survival in relapsed multiplemyeloma. Clin Cancer Res 2002; 8:3377-82.6Yakoub-Agha I, Michel Attal M, Charles Dumontet C et al Thalidomide in patients with advanced multiple myeloma: a studyof 83 patients-report of the Intergroupe Francophone du Myelome (IFM). Hematol J 2002; 3:185-92.7Mileshkin L, Biagi JJ, Mitchell P, et al. Multicenter phase 2 trial of thalidomide in relapsed/refractory multiple myeloma:adverse prognostic impact of advanced age. Blood 2003; 102:69-77.8Juliusson G, Celsing F, Turesson I, et al. Frequent good partial remissions from thalidomide including best response ever inpatients with advanced refractory and relapsed myeloma. Br J Haematol 2000; 109:89-96.9Anagnostopoulos A, Weber D, Rankin K, et al. Thalidomide and dexamethasone for resistant multiple myeloma. Br JHaematol 2003; 121:768-71.10Dimopoulos MA, Zervas K, Kouvatseas G et al. Thalidomide and dexamethasone combination for refractory multiplemyeloma. Ann Oncol 2001; 12:991-5.11Palumbo A, Bertola A, Falco P, et al. Efficacy of low-dose thalidomide and dexamethasone as first salvage regimen inmultiple myeloma. Hematol J 2004; 5:318-324.12Moehler T, Kai Neben K, Axel Benner A et al. Salvage therapy for multiple myeloma with thalidomide and CEDchemotherapy. Blood 2001; 98: 3846-8.13Garcia-Sanz R, Gonzalez-Fraile MI, Sierra M et al. The combination of thalidomide, cyclophosphamide and dexamethasone(ThaCyDex) is feasible and can be an option for relapsed/refractory multiple myeloma. Hematol J 2002; 3:43-8.14Kropff M, Lang N, Bisping G et al. Hyperfractionated cyclophosphamide in combination with pulsed dexamethasone andthalidomide (HyperCDT) in primary refractory or relapsed multiple myeloma. Br J Haematol 2003; 122:607-16.15Dimopoulos MA, Hamilos G, Zomas A, et al. Pulsed cyclophosphamide, thalidomide and dexamethasone: an oral regimen
LA TALIDOMIDE NEL MIELOMA MULTIPLO 43for previously treated patients with multiple mieloma. Hematol J 2004; 5:112-117.16Lee CK, Barlogie B, Munshi N et al. DTPACE: an effective, novel combination chemotherapy with thalidomide forpreviously treated patients with myeloma. J Clin Oncol 2003; 21:2732-9.17Srkalovic G, Elson P, Trebisky B et al. Use of melphalan, thalidomide, and dexamethasone in treatment of refractory andrelapsed multiple myeloma. Med Oncol 2002; 19:219-26.18Weber D, Rankin K, Gavino M et al Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. JClin Oncol 2003; 21:16-9.19Cavo M, Zamagni E, Tosi P, et al. Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. Blood 2005;106:35-9.20Rajkumar SV, Hayman S, Gertz MA et al Combination therapy with thalidomide plus dexamethasone for newly diagnosedmyeloma. J Clin Oncol 2002; 20:4319-23.21Alexanian R, Weber D, Giralt S, Delasalle K. Consolidation therapy of multiple myeloma with thalidomide-dexamethasoneafter intensive chemotherapy. Ann Oncol. 2002; 13:1116-9.22Attal M, Harousseau JL, Leyvraz S et al. Maintenance treatment with thalidomide after autologous transplantation formyeloma: first analysis of a prospective randomized study of Intergroupe Francophone du Myelome (IFM 99 02), Blood 2004;104:535a.23Zervas K, Dimopoulos MA, Hatzicharissi E, et al. Primary treatment of multiple mieloma with thalidomide, vincristine,liposomal doxorubicin and dexamethasone (T-VAD doxil): a phase II mutlicenter study. Ann Oncol 2004; 15:134-138.24Schutt P, Ebelin P, Buttkereit U, et al. Thalidomide in combination with vincristine, epirubicin and dexamethasone (VED)for previously untreated patients with multiple mieloma. Eur J Haematol 2005; 74:40-46.25Palumbo A, Bertola A, Musto P et al. A prospective randomized trial of oral melphalan, prednisone, thalidomide (MPT) vsoral melphalan, prednisone (MP): an interim analysis. Blood 2004; 104 (11):207a.26Hassoun H, Reich L, Klimek VM, et al. Doxorubicin and dexamethasone followed by thalidomide and dexamethasone(AD-TD) as initial therapy for symptomatic patients with multiple mieloma. Blood 2004; 104:2409a.27Durie BGE and Stepan DE. Low dose thalidomide alone and in combination: long term follow up. Blood 2001; 98:492-4.28Wechalekar AD, Chen CI, Sutton D, et al. Intermediate dose thalidomide (200 mg daily) has comparable efficacy and lesstoxicity than higher doses in relapsed multiple myeloma. Leuk Lymphoma 2003; 44:1147-4.29Leleu X, Magro L, Fawaz A, et al. Efficacy of a low dose thalidomide in advanced multiple myeloma. Blood 2002;100:1519-20.
Page 1 and 2: Il Libro Italiano della Talidomide
Page 3 and 4: I N T R O D U Z I O N E 3Quarant’
Page 5 and 6: I N T R O D U Z I O N E 5di natura
Page 7 and 8: P R E F A Z I O N E 7Quando mi è s
Page 9 and 10: P R E F A Z I O N E 9Questo program
Page 11 and 12: P R E F A Z I O N E 11L’Agenzia d
Page 13 and 14: 13Alla fine degli anni ’50 la tal
Page 15 and 16: BREVE STORIA DELLA TALIDOMIDE IN IT
Page 23 and 24: UN PARERE ESPERTO: “TALIDOMIDE E
Page 25 and 26: LA TALIDOMIDE, DALLA STORIA ALLA FA
Page 37 and 38: LA TALIDOMIDE NEL MIELOMA MULTIPLO
Page 39 and 40: LA TALIDOMIDE NEL MIELOMA MULTIPLO
Page 41: LA TALIDOMIDE NEL MIELOMA MULTIPLO
Page 45 and 46: LA TALIDOMIDE IN ONCOLOGIA 45La tal
Page 47 and 48: LA TALIDOMIDE IN ONCOLOGIA 47con il
Page 49 and 50: LA TALIDOMIDE IN ONCOLOGIA 49In que
Page 51 and 52: TALIDOMIDE NEL TRATTAMENTO DELL’
Page 57 and 58: ATTUALITÀ E PROSPETTIVE IN DERMATO

Il Libro Italiano della Talidomide... - a.na.d.ma.

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?